Amgen, AstraZeneca announce top-line results from WAYPOINT trial
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...
Yahoo Finance1 小时
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with ...
"Chronic rhinosinusitis with nasal polyps negatively impact patients’ daily lives with obstructions leading to disturbances in smell, taste and sleep as well as pain and fatigue. The impressive data ...
来自MSN2 小时
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy
Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...
Buy4 小时
AstraZeneca touts positive results from nasal polyp treatment study
(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
Are Sinus Infections Contagious? Here's What 3 MDs Have to Say
A sinus infection, also known as sinusitis, occurs when the air cavities around your nasal passages become inflamed and ...